Company news
AtaiBeckley Inc. news in 2023
AtaiBeckley Inc.'s news releases, calls and decks from 2023, newest first.
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
November 13, 2023
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
October 16, 2023
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
October 5, 2023
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
October 1, 2023
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 13, 2023
atai Life Sciences to Participate in Upcoming September Investor Conferences
September 5, 2023
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
August 9, 2023
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
August 7, 2023
atai Life Sciences to Participate in Upcoming June Investor Conferences
May 31, 2023
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
May 10, 2023
atai Life Sciences to Participate in Upcoming May Investor Conference
May 1, 2023
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
April 27, 2023
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
April 12, 2023
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
March 23, 2023
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
March 5, 2023
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
February 28, 2023
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
January 8, 2023
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
January 5, 2023